Machine Learning Can Significantly Impact Sepsis Diagnostics, Which Has Led To Significant Investment in the Field
Sepsis
diagnostics is the term given to a generic medical diagnostics for a specific
condition that causes fluid accumulation in the lower parts of the body. The
exact cause of the condition remains unknown to most doctors; however, the most
common cause is bacterial infection. Common symptoms include a high fever,
nausea, chills, vomiting, diarrhea and stomach pain. These symptoms are
generally caused by the body's attempt to combat foreign matters that are known
to be harmful to health.
High
prevalence of sepsis is expected to boost demand for sepsis diagnostics. According
to the study, ‘Epidemiology of neonatal early-onset sepsis in a geographically
diverse Australian health district 2006-2016’, published in PLOS One in 2019,
among 93,584 live born babies, 65 had confirmed early-onset sepsis (0.69/1000
live births).
Machine
learning can significantly impact sepsis
diagnostics, which has led to significant investment in the field. In
October 2019, the Biomedical
Advanced Research and Development Authority, U.S. Department of Health and
Human Services, awarded Beckman Coulter, Inc. a contract of US$ 1.25 million to
develop and commercialize a novel machine-learning-based sepsis detection
algorithm. Hematology analyzers play a major role in diagnosis of sepsis. In
May 2020, Beckman Coulter launched its
DxH 690T hematology analyzer featuring mid-volume laboratories advanced
features such as the Early Sepsis Indicator in the U.S. Earlier, in April 2019,
the company also received 510(k) clearance from the U.S. Food and Drug
Administration for its Early Sepsis Indicator, a hematology-based cellular
biomarker that is designed to help emergency department physicians identify
patients with sepsis or at increased risk of developing sepsis.
Blood
gas analyzers are used in identifying sepsis biomarkers. In September 2019, Radiometer
Ltd. demonstrated its range of point of care solutions at the Institute of
Biomedical Science (IBMS) Congress 2019, held in the U.K., with new features
such as ABL90 FLEX PLUS blood gas analyzer with creatinine and urea and AQT90
FLEX immunoassay analyzer including sepsis biomarkers.
Comments
Post a Comment